Citations

Clear

3030 citation(s) found for "Susan, M".

2023 HRS/EHRA/APHRS/LAHRS Expert Consensus Statement on Practical Management of the Remote Device Clinic
Ferrick, Aileen M., Kojodjojo, Pipin , López-Cabanillas, Néstor , Chew, Derek S. , Choi, Jong‐Il , Dagres, Nikolaos , Dalal, Aarti , Dechert, Brynn E. , Frazier‐Mills, Camille, Gilbert, Olivia , Hewit, Sherri, Kneeland, Christine , Mirza, Starr DeEllen, Runté, Mary, Sinclair, Susan, Teixeira, Ricardo Alkmim , Vandenberk, Bert , Reviewers, Document, Davenport, Elizabeth , Freedenberg, Vicki , Glotzer, Taya V. , Ikeda, Takanori , Kramer, Daniel B. , Lin, David , Rojel‐Martínez, Ulises, Stühlinger, Markus , Varosy, Paul D. , Huang, Jin-Long, Rojel-Martínez, Ulises, Dagres, Nikolaos , Raj, Satish R , Deneke, Thomas , Abe, Haruhiko , Bovéda, Serge , Han, Janet K. , Mittal, Suneet , Ricci, Renato Pietro , Teixeira, Ricardo Alkmim , Vandenberk, Bert , Varma, Niraj , Reviewers, Document, Huang, Jin‐Long

Mayo Clinic

Journal of Arrhythmia | May 19, 2023 | Volume: 39 | Issue: 3 | Pages: 250-302

10.1002/joa3.12851 | PMID 37324757 Get It

AbstractRemote monitoring is beneficial for the management of patients with cardiovascular implantable electronic devices by impacting morbidity and mortality. With increasing numbers of patients using remote monitoring, keeping up with higher volume of remote monitoring transmissions creates challenges for device clinic staff. This international multidisciplinary document is intended to guide cardiac electrophysiologists, allied professionals, and hospital administrators in managing remote monitoring clinics. This includes guidance for remote monitoring clinic staffing, appropriate clinic workflows, patient education, and alert management. This expert consensus statement also addresses other topics such as communication of transmission results, use of third‐party resources, manufacturer responsibilities, and programming concerns. The goal is to provide evidence‐based recommendations impacting all aspects of remote monitoring services. Gaps in current knowledge and guidance for future research directions are also identified.
American Gastroenterological Association-American College of Gastroenterology Clinical Practice Guideline: Pharmacological Management of Chronic Idiopathic Constipation
Chey, William D. , Imdad, Aamer , Almario, Christopher V. , Bharucha, Adil E. , Diem, Susan J. , Greer, Katarina B. , Hanson, Brian, Harris, Lucinda A. , Ko, Cynthia W. , Patel, Amit , Shah, Eric D. , Sultan, Shahnaz , Patel, A , Imdad, Aamer , Shah, Eric D , Chang, Lin , Murad, M. Hassan , Lembo, Anthony

Mayo Clinic

American Journal of Gastroenterology | May 19, 2023 | Volume: 118 | Issue: 6 | Pages: 936-954

10.14309/ajg.0000000000002227 | PMID 37204227 Get It

INTRODUCTION: Chronic idiopathic constipation (CIC) is a common disorder associated with significant impairment in quality of life. This clinical practice guideline, jointly developed by the American Gastroenterological Association and the American College of Gastroenterology, aims to inform clinicians and patients by providing evidence-based practice recommendations for the pharmacological treatment of CIC in adults. METHODS: The American Gastroenterological Association and the American College of Gastroenterology formed a multidisciplinary guideline panel that conducted systematic reviews of the following agents: fiber, osmotic laxatives (polyethylene glycol, magnesium oxide, lactulose), stimulant laxatives (bisacodyl, sodium picosulfate, senna), secretagogues (lubiprostone, linaclotide, plecanatide), and serotonin type 4 agonist (prucalopride). The panel prioritized clinical questions and outcomes and used the Grading of Recommendations Assessment, Development, and Evaluation framework to assess the certainty of evidence for each intervention. The Evidence to Decision framework was used to develop clinical recommendations based on the balance between the desirable and undesirable effects, patient values, costs, and health equity considerations. RESULTS: The panel agreed on 10 recommendations for the pharmacological management of CIC in adults. Based on available evidence, the panel made strong recommendations for the use of polyethylene glycol, sodium picosulfate, linaclotide, plecanatide, and prucalopride for CIC in adults. Conditional recommendations were made for the use of fiber, lactulose, senna, magnesium oxide, and lubiprostone. DISCUSSION: This document provides a comprehensive outline of the various over-the-counter and prescription pharmacological agents available for the treatment of CIC. The guidelines are meant to provide a framework for approaching the management of CIC; clinical providers should engage in shared decision making based on patient preferences as well as medication cost and availability. Limitations and gaps in the evidence are highlighted to help guide future research opportunities and enhance the care of patients with chronic constipation.
Vigorous Exercise in Patients With Hypertrophic Cardiomyopathy
Lampert, Rachel , Ackerman, Michael J. , Marino, Bradley S. , Burg, Matthew M. , Ainsworth, Barbara E. , Tome, Maite , Abraham, Roselle, Balaji, Seshadri , Barth, Cheryl , Berul, Charles I. , Bos, Martijn, Cannom, David S. , Choudhury, Lubna , Concannon, Maryann, Cooper, Robert , Czosek, Richard J. , Dubin, Anne M. , Dziura, James, Eidem, Benjamin W., Etheridge, Susan P. , Geske, Jeffrey B. , Gray, Belinda , Lal, Ashwin K. , Ommen, Steven R., Saarel, Elizabeth V. , Simone, Laura, Tomaselli, Gordon F., Ware, James S. , Day, Sharlene M. , Abrahms, Dominic Jr, Ashley, Euan A. , Aziz, Peter F. , Batra, Anjan S. , Ferhaan, Ahmad, Gollob, Michael J., Kanter, Ronald J. , Li, Walter, Masri, Ahmad , Murphy, Ann Mooney, Popjes, Eric , Rao, Roopa S, Rosenthal, David N. , Semsarian, Chris, Shah, Maully J. , Tardif, Jill, Towbin, Jeffrey A. , Turer, Aslan T., Bos, J. Martijn , Eidem, Benjamin, Bos, Johan M , Dubin, Anne M , Ware, James S , Geske, Jeffrey B , Tome Esteban, Maria Teresa , Gray, Belinda , Salberg, Lisa , Ho, Carolyn Y. , Dziura, James, Emery, Michael S. , Estes, N.A. Mark , Hall, Kevin D. , Harmon, Kimberly G. , James, Cynthia A. , Law, Ian H. , Li, Fangyong , Link, Mark S. , McKenna, William J. , Molossi, Silvana M , Olshansky, Brian , Saberi, Sara , Zipes, Douglas P. , Cerrone, Marina , Colan, Steven D. , Erickson, Christopher, Ferhaan, Ahmad, Johnsrude, Christopher L. , Kannankeril, Prince J. , Murphy, Ann, Nandi, Deipanjan , Pérez, Marco , Perry, James C. , Rao, Roopa, Sanatani, Shubhayan , Skinner, Jonathan R. , Webster, Gregory , Wever‐Pinzon, Omar , Wong, Timothy C.

Mayo Clinic

JAMA Cardiology | May 17, 2023 | Volume: 8 | Issue: 6 | Pages: 595

10.1001/jamacardio.2023.1042 | PMID 37195701 Get It

Importance Whether vigorous intensity exercise is associated with an increase in risk of ventricular arrhythmias in individuals with hypertrophic cardiomyopathy (HCM) is unknown. Objective To determine whether engagement in vigorous exercise is associated with increased risk for ventricular arrhythmias and/or mortality in individuals with HCM. The a priori hypothesis was that participants engaging in vigorous activity were not more likely to have an arrhythmic event or die than those who reported nonvigorous activity. Design, Setting, and Participants This was an investigator-initiated, prospective cohort study. Participants were enrolled from May 18, 2015, to April 25, 2019, with completion in February 28, 2022. Participants were categorized according to self-reported levels of physical activity: sedentary, moderate, or vigorous-intensity exercise. This was a multicenter, observational registry with recruitment at 42 high-volume HCM centers in the US and internationally; patients could also self-enroll through the central site. Individuals aged 8 to 60 years diagnosed with HCM or genotype positive without left ventricular hypertrophy (phenotype negative) without conditions precluding exercise were enrolled. Exposures Amount and intensity of physical activity. Main Outcomes and Measures The primary prespecified composite end point included death, resuscitated sudden cardiac arrest, arrhythmic syncope, and appropriate shock from an implantable cardioverter defibrillator. All outcome events were adjudicated by an events committee blinded to the patient’s exercise category. Results Among the 1660 total participants (mean [SD] age, 39 [15] years; 996 male [60%]), 252 (15%) were classified as sedentary, and 709 (43%) participated in moderate exercise. Among the 699 individuals (42%) who participated in vigorous-intensity exercise, 259 (37%) participated competitively. A total of 77 individuals (4.6%) reached the composite end point. These individuals included 44 (4.6%) of those classified as nonvigorous and 33 (4.7%) of those classified as vigorous, with corresponding rates of 15.3 and 15.9 per 1000 person-years, respectively. In multivariate Cox regression analysis of the primary composite end point, individuals engaging in vigorous exercise did not experience a higher rate of events compared with the nonvigorous group with an adjusted hazard ratio of 1.01. The upper 95% 1-sided confidence level was 1.48, which was below the prespecified boundary of 1.5 for noninferiority. Conclusions and Relevance Results of this cohort study suggest that among individuals with HCM or those who are genotype positive/phenotype negative and are treated in experienced centers, those exercising vigorously did not experience a higher rate of death or life-threatening arrhythmias than those exercising moderately or those who were sedentary. These data may inform discussion between the patient and their expert clinician around exercise participation.
A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2+ Breast Cancer
Veeraraghavan, Jamunarani , Gutiérrez, Carolina , Angelis, Carmine De , Davis, Robert , Wang, Tao , Pascual, Tomás , Selenica, Pier , Sanchez, Katherine , Nitta, Hiroaki , Kapadia, Monesh , Pavlick, Anne C. , Rexer, Brent N. , Forero-Torres, Andres , Nanda, Rita , Storniolo, Anna Maria , Krop, Ian E. , Nangia, Julie R. , Weigelt, Britta , Prat, Aleix , Osborne, C. Kent , Rimawi, Mothaffar F. , De Angelis, Carmine , Galvan, Patricia , Rexer, Brent , Forero-Torres, Andres , Nanda, Rita , Storniolo, Anna M , Krop, Ian E , Goetz, Matthew P , Nangia, Julie R , Wolff, Antonio C , Weigelt, Britta , Reis-Filho, Jorge S , Hilsenbeck, Susan Galloway , Prat, Aleix , Osborne, C Kent , Schiff, Rachel , Rimawi, Mothaffar , Wang, Tao , Goetz, Matthew P. , Wolff, Antonio C. , Reis‐Filho, Jorge S. , Schiff, Rachel

Mayo Clinic

Clinical Cancer Research | May 17, 2023 | Volume: 29 | Issue: 16 | Pages: 3101-3109

10.1158/1078-0432.ccr-22-3753 | PMID 37195235 Get It

Abstract Purpose: Clinical trials reported 25% to 30% pathologic complete response (pCR) rates in HER2+ patients with breast cancer treated with anti-HER2 therapies without chemotherapy. We hypothesize that a multiparameter classifier can identify patients with HER2-“addicted” tumors who may benefit from a chemotherapy-sparing strategy. Experimental Design: Baseline HER2+ breast cancer specimens from the TBCRC023 and PAMELA trials, which included neoadjuvant treatment with lapatinib and trastuzumab, were used. In the case of estrogen receptor–positive (ER+) tumors, endocrine therapy was also administered. HER2 protein and gene amplification (ratio), HER2-enriched (HER2-E), and PIK3CA mutation status were assessed by dual gene protein assay (GPA), research-based PAM50, and targeted DNA-sequencing. GPA cutoffs and classifier of response were constructed in TBCRC023 using a decision tree algorithm, then validated in PAMELA. Results: In TBCRC023, 72 breast cancer specimens had GPA, PAM50, and sequencing data, of which 15 had pCR. Recursive partitioning identified cutoffs of HER2 ratio ≥ 4.6 and %3+ IHC staining ≥ 97.5%. With PAM50 and sequencing data, the model added HER2-E and PIK3CA wild-type (WT). For clinical implementation, the classifier was locked as HER2 ratio ≥ 4.5, %3+ IHC staining ≥ 90%, and PIK3CA-WT and HER2-E, yielding 55% and 94% positive (PPV) and negative (NPV) predictive values, respectively. Independent validation using 44 PAMELA cases with all three biomarkers yielded 47% PPV and 82% NPV. Importantly, our classifier's high NPV signifies its strength in accurately identifying patients who may not be good candidates for treatment deescalation. Conclusions: Our multiparameter classifier differentially identifies patients who may benefit from HER2-targeted therapy alone from those who need chemotherapy and predicts pCR to anti-HER2 therapy alone comparable with chemotherapy plus dual anti-HER2 therapy in unselected patients.
A Novel PD-L1 Antibody Promotes Antitumor Function of Peripheral Cytotoxic Lymphocytes after Radical Nephrectomy in Patients with Renal Cell Carcinoma
An, Zesheng , Hsu, Michelle A. , Gicobi, Joanina K. , Xu, Tianxiao , Harrington, Susan M. , Pavelko, Kevin D. , Hirdler, Jacob B. , Lohse, Christine M. , Nabavizadeh, Reza , Pessoa, Rodrigo Rodrigues , Sharma, Vidit , Thompson, R. Houston, Leibovich, Bradley C. , Pavelko, Kevin D , Pessoa, Rodrigo R, Leibovich, Bradley C , Dong, Haidong , Lucien, Fabrice , Zhang, Henan , Dong, Haidong , Lucien, Fabrice

Mayo Clinic

The Journal of Immunology | May 10, 2023 | Volume: 210 | Issue: 12 | Pages: 2029-2037

10.4049/jimmunol.2200933 | PMID 37163328 Get It

Abstract The intrinsic and acquired resistance to PD-1/PD-L1 immune checkpoint blockade is an important challenge for patients and clinicians because no reliable tool has been developed to predict individualized response to immunotherapy. In this study, we demonstrate the translational relevance of an ex vivo functional assay that measures the tumor cell killing ability of patient-derived CD8 T and NK cells (referred to as “cytotoxic lymphocytes,” or CLs) isolated from the peripheral blood of patients with renal cell carcinoma. Patient-derived PBMCs were isolated before and after nephrectomy from patients with renal cell carcinoma. We compared the efficacy of U.S. Food and Drug Administration (FDA)-approved PD-1/PD-L1 inhibitors (pembrolizumab, nivolumab, atezolizumab) and a newly developed PD-L1 inhibitor (H1A Ab) in eliciting cytotoxic function. CL activity was improved at 3 mo after radical nephrectomy compared with baseline, and it was associated with higher circulating levels of tumor-reactive effector CD8 T cells (CD11ahighCX3CR1+GZMB+). Treatment of PBMCs with FDA-approved PD-1/PD-L1 inhibitors enhanced tumor cell killing activity of CLs, but a differential response was observed at the individual-patient level. H1A demonstrated superior efficacy in promoting CL activity compared with FDA-approved PD-1/PD-L1 inhibitors. PBMC immunophenotyping by mass cytometry revealed enrichment of effector CD8 T and NK cells in H1A-treated PBMCs and immunosuppressive regulatory T cells in atezolizumab-treated samples. Our study lays the ground for future investigation of the therapeutic value of H1A as a next-generation immune checkpoint inhibitor and the potential of measuring CTL activity in PBMCs as a tool to predict individual response to immune checkpoint inhibitors in patients with advanced renal cell carcinoma.
NCCN Guidelines® Insights: Distress Management, Version 2.2023
Riba, Michelle B., Donovan, Kristine A. , Ahmed, Kauser , Braun, IIana, Breitbart, William , Brewer, Benjamin W. , Corbett, Cheyenne , Fleishman, Stewart B., Garcia, Sofia F. , Greenberg, Donna, Handzo, George , Hoofring, Laura, Hutchinson, Sean Z., Johns, Shelley A. , Keller, Jennifer A. , Kumar, Pallavi , Lahijani, Sheila , Martin, Sara , Niazi, Shehzad K. , Pailler, Megan E. , Parnes, Francine, Salman, Jaroslava, Scher, Eli D. , Schuster, Jessica , Teply, Melissa , Usher, A., Valentine, Alan , Vanderlan, Jessica, Lyons, Megan S., McMillian, Nicole R., Darlow, Susan, Garcia, Sofia F , Andersen, Barbara L. , Fann, Jesse R. , Huang, Chao‐Hui , Rao, Vinay P.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | May 8, 2023 | Volume: 21 | Issue: 5 | Pages: 450-457

10.6004/jnccn.2023.0026 | PMID 37156476 Get It

These NCCN Guidelines for Distress Management discuss the identification and treatment of psychosocial problems in patients with cancer. All patients experience some level of distress associated with a cancer diagnosis and the effects of the disease and its treatment regardless of the stage of disease. Clinically significant levels of distress occur in a subset of patients, and identification and treatment of distress are of utmost importance. The NCCN Distress Management Panel meets at least annually to review comments from reviewers within their institutions, examine relevant new data from publications and abstracts, and reevaluate and update their recommendations. These NCCN Guidelines Insights describe updates to the NCCN Distress Thermometer (DT) and Problem List, and to the treatment algorithms for patients with trauma- and stressor-related disorders.
International Epidemiology of Carbapenemase-Producing Escherichia coli
Boutzoukas, Angelique E , Komarow, Lauren , Chen, Liang , Hanson, Blake , Liu, Zhengyin , Mendoza, Soraya Salcedo, Ordóñez, Karen , Wang, Minggui , Ge, Lizhao , Giri, Abhigya, Hill, Carol , Baum, Keri, Kreiswirth, Barry N. , Patel, Robin , Arias, César A. , Chambers, Henry F. , Fowler, Vance G. , Investigators, Multi-Drug Resistant Organism Network, Souha, S Kanj, Jean, Francois Jabbour, Fujie, Zhang, Judith, J Lok, Robert, A Salata, Martin, Stryjewski, Valentina, Di Castelnuovo, Jose, Millan Oñate Gutierrez, Eric, Cober, Susan, Richter, Deverick, J Anderson, Beth, Evans, Carol, Hill, Heather, Reich, Keri, Baum, Rebekka, Arias, Vance, G Fowler, Karen, Ordoñez, Jesse, T Jacob, Li, Linghua , Barry, Neil, Samit, Desai, Erica, Herc, Ezequiel, Cordova, Maria, R Ponisio, Samuel, Vichez, Marisa, Laëtitia , Sandra, Valderrama, Jairo, Figueroa, Cesar, A Arias, An, Qiang , Diane, Panesso, Kirsten, R., Truc, Thanh, Jiachun, Su, Jiang, Jianping , Ming-gui, Wang, Xu, Xiaogang , Yang, Yang , Jose, M Munita, Maria, Spencer, Thamer, Alenazi, Robert, Alain, Steven, Hersch, Susan, Davies, Charles, Huskins, Kerry, G, Robin, Patel, Suzannah, Schmidt-Malan, Sara, Revolinski, Glenn, Wortmann, Robert, C Kalayjian, Greg, Weston, Belinda, Ostrowsky, Gopi, Patel, Daniel, E Furst, Angela, Kim, Julia, Garcia-Diaz, Soraya, Salcedo, John, Jeffy, Zhengyin, Liu, Andrew, Henderson, David, Louis, Qing, Xie, Keith, S Kaye, Gao, Hainv , Yu, Yunsong , Mary, Waters, Bettina, C Fries, Brandon, Eilertson, Kean, Lee Chew, Nares, Smitasin, Paul, Ananth Tambyah, Jason, Christopher, Anton, Peleg, Marcel, L. Saint, Lan-juan, LI , Lauren, Komarow, Lizhao, Ge, Scott, Evans, Todd, McCarty, Henry, Fitjerald , Omai, B Garner, Lilian, M Abbo, David, van Duin, Ebbing, Lautenbach, Jennifer, Harrington, Yohei, Doi, Darren, W Logan, Blake, Hanson, Jinnethe, Reyes, Maria, Virginia Villegas Botero, Lorena, Diaz, Federico, P., Ritu, Banerjee, Sorabh, Dhar, Michael, Joy S, Zhiyong, Zong, Stryjewski, Martín E. , Villegas, María Virginia , Wang, Minggui , Evans, Scott R , Patel, Robin , van Duin, David , Pérez, Federico , Jiang, Jianping , Boutzoukas, Angelique , Chen, Liang , Villegas, Maria Virginia , Kanj, Souha S. , Paterson, David L. , Evans, Scott , Bonomo, Robert A. , Kreiswirth, Barry N , Arias, César A. , Fowler, Vance G. , Investigators, Multi-Drug Resistant Organism Network, Souha, S Kanj, Fujie, Zhang, Jose, Millan-Onate, Eric, Cober, Barry, N Kreiswirth, Claudia, Manca, Marisa, L Sanchez, An, Q Dinh, Kirsten, Rydell, Hu, Fupin , Maria, Spencer-Sandino, Robert, A Bonomo, Steven, H Marshall, Susan, D Rudin, Glenn, Wortmann, Gopi, Patel, Zhengyin, Liu, David, L Paterson, Qing, Xie, Marimuthu, Kalisvar , Anton, Peleg, Henry, F Chambers, Ebbing, Lautenbach, Jennifer, H Han, Lorena, Diaz, Federico, Perez, Ritu, Banerjee, Zhiyong, Zong

Mayo Clinic

Clinical Infectious Diseases | May 8, 2023 | Volume: 77 | Issue: 4 | Pages: 499-509

10.1093/cid/ciad288 | PMID 37154071 Get It

Abstract Background Carbapenemase-producing (CP) Escherichia coli (CP-Ec) are a global public health threat. We aimed to describe the clinical and molecular epidemiology and outcomes of patients from several countries with CP-Ec isolates obtained from a prospective cohort. Methods Patients with CP-Ec were enrolled from 26 hospitals in 6 countries. Clinical data were collected, and isolates underwent whole-genome sequencing. Clinical and molecular features and outcomes associated with isolates with or without metallo-β-lactamases (MBLs) were compared. The primary outcome was desirability of outcome ranking (DOOR) at 30 days after the index culture. Results Of the 114 CP-Ec isolates in Consortium on resistance against carbapenems in Klebsiella and other Enterobacterales-2 (CRACKLE-2), 49 harbored an MBL, most commonly blaNDM-5 (38/49, 78%). Strong regional variations were noted with MBL-Ec predominantly found among patients in China (23/49). Clinically, MBL-Ec were more often from urine sources (49% vs 29%), less often met criteria for infection (39% vs 58%, P = .04), and had lower acuity of illness when compared with non–MBL-Ec. Among patients with infection, the probability of a better DOOR outcome for a randomly selected patient with MBL-Ec as compared with non–MBL-Ec was 62% (95% CI: 48.2–74.3%). Among infected patients, non–MBL-Ec had increased 30-day (26% vs 0%; P = .02) and 90-day (39% vs 0%; P = .001) mortality compared with MBL-Ec. Conclusions Emergence of CP-Ec was observed with important geographic variations. Bacterial characteristics, clinical presentations, and outcomes differed between MBL-Ec and non–MBL-Ec. Mortality was higher among non-MBL isolates, which were more frequently isolated from blood, but these findings may be confounded by regional variations.
Deletion of SERF2 in mice delays embryonic development and alters amyloid deposit structure in the brain
Stroo, Esther, Janssen, Leen , Sin, Olga , Hogewerf, Wytse, Koster, Mirjam H. , Harkema, Liesbeth , Beschörner, Natalie , Wolters, Anouk H. G. , Bakker, Björn , Marschall, Susan , Hoelter, Sabine M., Fuchs, Helmut , Gailus‐Durner, Valérie , Angelis, Martin Hrabě de , Thathiah, Amantha , Foijer, Floris , Sluis, Bart van de , Deursen, Jan van, Jucker, M., Nollen, Ellen A. A. , Bakker, Bjorn , Becker, Lore , Marschall, Susan , Wurst, Wolfgang , Hrabe de Angelis, Martin , Thathiah, Amantha , Foijer, Floris , van Deursen, Jan, Nollen, Ellen Aa , van de Sluis, Bart , Youssef, Sameh A. , Garrett, Lillian , Hölter, Sabine M. , Bruin, Alain de

Mayo Clinic

Life Science Alliance | May 2, 2023 | Volume: 6 | Issue: 7 | Pages: e202201730

10.26508/lsa.202201730 | PMID 37130781 Get It

In age-related neurodegenerative diseases, like Alzheimer’s and Parkinson’s, disease-specific proteins become aggregation-prone and form amyloid-like deposits. Depletion of SERF proteins ameliorates this toxic process in worm and human cell models for diseases. Whether SERF modifies amyloid pathology in mammalian brain, however, has remained unknown. Here, we generated conditional Serf2 knockout mice and found that full-body deletion of Serf2 delayed embryonic development, causing premature birth and perinatal lethality. Brain-specific Serf2 knockout mice, on the other hand, were viable, and showed no major behavioral or cognitive abnormalities. In a mouse model for amyloid-β aggregation, brain depletion of Serf2 altered the binding of structure-specific amyloid dyes, previously used to distinguish amyloid polymorphisms in the human brain. These results suggest that Serf2 depletion changed the structure of amyloid deposits, which was further supported by scanning transmission electron microscopy, but further study will be required to confirm this observation. Altogether, our data reveal the pleiotropic functions of SERF2 in embryonic development and in the brain and support the existence of modifying factors of amyloid deposition in mammalian brain, which offer possibilities for polymorphism-based interventions.
Inclusion of Comorbidities and Prognosis in U.S. States' Triage Plans During COVID-19
Ennis, Jackson S, Nguyen, N.V. , Kramer, D.B., Smith, Andrew , Sulmasy, Dan, Tilburt, Jon C. , DeMartino, Erin S. , Ennis, Jackson S. , Riggan, Kirsten A. , Wolf, Susan M.

Mayo Clinic

D93. CLINICAL AND TRANSLATIONAL STUDIES OF COVID-19 CRITICAL ILLNESS | May 1, 2023 | Volume: No volume available | Issue: No issue available | Pages: A6554-A6554

10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a6554 Get It

Caring for Critically Ill Children With the ICU Liberation Bundle (ABCDEF): Results of the Pediatric Collaborative*
Srivastava, Avantika , Jennison, Susan, Simino, Megan, Traube, Chani , LaRose, Kimberly, Kawai, Yu , Neu, Lori, Kudchadkar, Sapna R. , Wieczorek, Beth, Hajnik, Krista, Kordik, Christina, Kumar, Vishakha K. , Aghamohammadi, Sara, Arteaga, Grace M. , Smith, Heidi A. B. , Orman, Andrea, Landman, Becky McGee, Valdivia, Hector , Browne, H Ilayward's, Fang, Timothy, Zimmerman, Jerry J. , Collaborative, for the Society of Critical Care Medicine’s Pediatric ICU Liberation Campaign, Landman, Bennett A , Lin, John C. H. , Malone, Sara M. , Spentzas, Thomas , Collaborative, for the Society of Critical Care Medicine’s Pediatric ICU Liberation Campaign

Mayo Clinic

Pediatric Critical Care Medicine | May 1, 2023 | Volume: 24 | Issue: 8 | Pages: 636-651

10.1097/pcc.0000000000003262 | PMID 37125798 Get It

OBJECTIVES: Assess clinical outcomes following PICU Liberation ABCDEF Bundle utilization. DESIGN: Prospective, multicenter, cohort study. SETTING: Eight academic PICUs. PATIENTS: Children greater than 2 months with expected PICU stay greater than 2 days and need for mechanical ventilation (MV). INTERVENTIONS: ABCDEF Bundle implementation. MEASUREMENT AND MAIN RESULTS: Over an 11-month period (3-mo baseline, 8-mo implementation), Bundle utilization was measured for 622 patients totaling 5,017 PICU days. Risk of mortality was quantified for 532 patients (4,275 PICU days) for correlation between Bundle utilization and MV duration, PICU length of stay (LOS), delirium incidence, and mortality. Utilization was analyzed as subject-specific (entire PICU stay) and day-specific (single PICU day). Median overall subject-specific utilization increased from 50% during the 3-month baseline to 63.9% during the last four implementation months ( p < 0.001). Subject-specific utilization for elements A and C did not change; utilization improved for B (0–12.5%; p = 0.007), D (22.2–61.1%; p < 0.001), E (17.7–50%; p = 0.003), and F (50–79.2%; p = 0.001). We observed no association between Bundle utilization and MV duration, PICU LOS, or delirium incidence. In contrast, on adjusted analysis, every 10% increase in subject-specific utilization correlated with mortality odds ratio (OR) reduction of 34%, p < 0.001; every 10% increase in day-specific utilization correlated with a mortality OR reduction of 1.4% ( p = 0.006). CONCLUSIONS: ABCDEF Bundle is applicable to children. Although enhanced Bundle utilization correlated with decreased mortality, increased utilization did not correlate with duration of MV, PICU LOS, or delirium incidence. Additional research in the domains of comparative effectiveness, implementation science, and human factors engineering is required to understand this clinical inconsistency and optimize PICU Liberation concept integration into clinical practice.